Gene Mutations in the Succinate Dehydrogenase Subunit SDHB Cause Susceptibility to Familial Pheochromocytoma and to Familial Paraganglioma
Open accessThe DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.
Abstract
The pheochromocytomas are an important cause of secondary hypertension. Although pheochromocytoma susceptibility may be associated with germline mutations in the tumor-suppressor genes VHL and NF1 and in the proto-oncogene RET, the genetic basis for most cases of nonsyndromic familial pheochromocytoma is unknown. Recently, pheochromocytoma susceptibility has been associated with germline SDHD mutations. Germline SDHD mutations were originally described in hereditary paraganglioma, a dominantly inherited disorder characterized by vascular tumors in the head and the neck, most frequently at the carotid bifurcation. The gene products of two components of succinate dehydrogenase, SDHC and SDHD, anchor the gene products of two other components, SDHA and SDHB, which form the catalytic core, to the inner-mitochondrial membrane. Although mutations in SDHC and in SDHD may cause hereditary paraganglioma, germline SDHA mutations are associated with juvenile encephalopathy, and the phenotypic consequences of SDHB mutations have not been defined. To investigate the genetic causes of pheochromocytoma, we analyzed SDHB and SDHC, in familial and in sporadic cases. Inactivating SDHB mutations were detected in two of the five kindreds with familial pheochromocytoma, two of the three kindreds with pheochromocytoma and paraganglioma susceptibility, and 1 of the 24 cases of sporadic pheochromocytoma. These findings extend the link between mitochondrial dysfunction and tumorigenesis and suggest that germline SDHB mutations are an important cause of pheochromocytoma susceptibility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“germline mutations in the B, C and D subunits of SDH predispose individuals to hereditary paragangliomatosis with phaeochromocytomas (HPGL) (2 -6)”
From Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations (2005) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, a biallelic loss of succinate dehydrogenase (SDH), an alteration found in familial paragangliomas and pheochromocytomas, as well as in a subset of sporadic gastrointestinal stromal tumors, creates a build-up of succinate (Astuti et al., 2001; Janeway et al., 2011).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Astuti et al., 2001
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The results of a clinical study further confirmed this observation by showing that patients with nonmetastatic lung cancer harbored loss-of-function mutations in SDH5128.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [128]
Experimental — accuracy not yet measuredIn the citing paper
“In cancer cells, mutations in succinate dehydrogenase subunit B (SDHB) cause susceptibility to familial pheochromocytoma99 and familial paraganglioma100 as well as gastrointestinal stromal tumors101.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [99]
In the citing paper
“In addition to the tumorigenic effects of succinate accumulation, SDH5 mutation is the key driver supporting the acquisition of epithelial–mesenchymal transition (EMT) characteristics.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [128]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Green, D. R., & Reed, J. C. (1998) · Science · doi:10.1126/science.281.5381.1309 · Cited by 8,965
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180 · cited 2×
“…cancers and in mouse models, results in up-regulation of angiogenic growth factors, such as vascular endothelial growth factor, secondary to a defect in ubiquitylation of the a-subunits of the HIF-1 and the HIF-2 transcription factors (Maxwell et al. 1999; Cockman et al. 2000; Ohh et al. 2000).”
BackgroundSelf-citationMutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638 · cited 3×
“…the iron-sulfur–protein subunit) and in both SDHC and SDHD (i.e., the genes for the integral membrane–protein subunits) are associated with neoplasia (Baysal et al. 2000; Niemann and Muller 2000; present study), autosomal recessive homozygous SDHA (i.e., the gene for the flavoprotein subunit)…”
BackgroundOhh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577 · cited 2×
“…cancers and in mouse models, results in up-regulation of angiogenic growth factors, such as vascular endothelial growth factor, secondary to a defect in ubiquitylation of the a-subunits of the HIF-1 and the HIF-2 transcription factors (Maxwell et al. 1999; Cockman et al. 2000; Ohh et al. 2000).”
BackgroundCockman, M. E., Masson, N., Mole, D. R., Jaakkola, P., Chang, G.-W., Clifford, S. C., Maher, E. R., Pugh, C. W., Ratcliffe, P. J., & Maxwell, P. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002740200 · Cited by 1,050 · cited 1×
“…cancers and in mouse models, results in up-regulation of angiogenic growth factors, such as vascular endothelial growth factor, secondary to a defect in ubiquitylation of the a-subunits of the HIF-1 and the HIF-2 transcription factors (Maxwell et al. 1999; Cockman et al. 2000; Ohh et al. 2000).”
BackgroundSelf-citationMutations in SDHC cause autosomal dominant paraganglioma, type 3
Niemann, S., & Müller, U. (2000) · Nature Genetics · doi:10.1038/81551 · Cited by 875 · cited 4×
“…herein: PGL1 (MIM 168000), which results from SDHD mutations at 11q23; PGL2 (MIM 601650), which maps to 11q13, although the causative gene has not been identified (Mariman et al. 1995); and PGL3 (MIM 605373), which results from SDHC mutations at 1q21 (Baysal et al. 2000; Niemann and Muller 2000).”
BackgroundInfluentialBourgeron, T., Rustin, P., Chretien, D., Birch-Machin, M., Bourgeois, M., Viegas-Péquignot, E., Munnich, A., & Rötig, A. (1995) · Nature Genetics · doi:10.1038/ng1095-144 · Cited by 730 · cited 2×
“SDHA mutations are associated with juvenile encephalopathy (Bourgeron et al. 1995), and the phenotypic consequences of SDHB mutations have not been defined.”
BackgroundHoffman, M. A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1019 · Cited by 382 · cited 1×
“Interestingly, germline VHL mutations that predispose patients to pheochromocytoma do not impair HIF-1a ubiquitylation (Clifford et al. 2001; Hoffman et al. 2001).”
BackgroundClifford, S. C. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1029 · Cited by 373
Gimm, O., Armanios, M. Y., Dziema, H., Neumann, H. P. H., & Eng, C. (2000) · PubMed · Cited by 274
Self-citation
Cited by
Items 401–500 of 999
Clinical Characteristics of Pheochromocytoma Patients With Germline Mutations in SDHD
Dannenberg, H., van Nederveen, F. H., Abbou, M., Verhofstad, A. A. J., Komminoth, P., de Krijger, R. R., & Dinjens, W. N. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.198 · Cited by 46
Ishii, T., Miyazawa, M., Onodera, A., Yasuda, K., Kawabe, N., Kirinashizawa, M., Yoshimura, S., Maruyama, N., Hartman, P. S., & Ishii, N. (2011) · Mitochondrion · doi:10.1016/j.mito.2010.09.006 · Cited by 42
“PGL1, PGL3, and PGL4 have been associated with germline mutations in the SDHB, SDHC, and SDHD subunits of SDH (Astuti et al., 2001; Niemann and Muller, 2000; Baysal et al., 2000).”
BackgroundKaipparettu, B. A., Ma, Y., & Wong, L. C. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05621.x · Cited by 45
The genetics of paragangliomas
Burnichon, N., Abermil, N., Buffet, A., Favier, J., & Gimenez‐Roqueplo, A. (2012) · European Annals of Otorhinolaryngology Head and Neck Diseases · doi:10.1016/j.anorl.2012.04.007 · Cited by 43
“The PGL1 locus is situated on hromosomal band 11q21 [4], PGL2 on 11q13 [5], PGL3 on q21 [6] and PGL4 on 1p36 [7].”
BackgroundCurrent diagnostic imaging of pheochromocytomas and implications for therapeutic strategy (Review)
Čtvrtlík, F., Koranda, P., Schovánek, J., Škarda, J., Hartmann, I., & Tüdös, Z. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.5871 · Cited by 63
“Furthermore, familial paraganglioma syndromes are associated with mutations in genetic encoding for the enzyme succinate dehydrogenase subunits A, B, C, and D (SDHA, SDHB, SDHC, and SDHD) (14-17).”
BackgroundRole of coenzymes in cancer metabolism
Thapa, M., & Dallmann, G. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.027 · Cited by 49
A Guide to Pheochromocytomas and Paragangliomas
Guilmette, J. M., & Sadow, P. M. (2019) · Surgical pathology clinics · doi:10.1016/j.path.2019.08.009 · Cited by 49
Targeting fuel pocket of cancer cell metabolism: A focus on glutaminolysis
Sharma, S., Agnihotri, N., & Kumar, S. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114943 · Cited by 46
Genetic defects in the oxidative phosphorylation (OXPHOS) system
Janssen, R. J. R. J., van den Heuvel, L. P., & Smeitink, J. A. M. (2004) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.4.2.143 · Cited by 41
Bailey, P. S. J., & Nathan, J. A. (2018) · Biomedicines · doi:10.3390/biomedicines6020060 · Cited by 41
“Mutations in the succinate dehydrogenase (SDH) subunits (mainly SDHB and SDHD) lead to familial paraganglioma syndromes [22,23], and it has been noted that some of these tumours resemble the hypoxia-induced carotid body enlargement observed in individuals living at high altitudes [23].”
BackgroundParanagama, M. P., Sakamoto, K., Amino, H., Awano, M., Miyoshi, H., & Kita, K. (2010) · Mitochondrion · doi:10.1016/j.mito.2009.12.145 · Cited by 40
Mitochondrial and glycolytic metabolic compartmentalization in diffuse large B-cell lymphoma
Gooptu, M., Whitaker‐Menezes, D., Sprandio, J. D., Domingo‐Vidal, M., Lin, Z., Uppal, G. K., Gong, J. Z., Fratamico, R., Leiby, B. E., Dulau‐Florea, A., et al. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.10.002 · Cited by 42
Imaging Features of Succinate Dehydrogenase–deficient Pheochromocytoma-Paraganglioma Syndromes
Withey, S. J., Perrio, S., Christodoulou, D., Izatt, L., Carroll, P., Velusamy, A., Obholzer, R., Lewington, V. J., & Jacques, A. (2019) · Radiographics · doi:10.1148/rg.2019180151 · Cited by 41
Lee, H., Jeong, S., Yu, Y., Kang, J., Sun, H., Rhee, J., & Kim, Y. H. (2019) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2019-106324 · Cited by 48
Mechanisms Governing Metabolic Heterogeneity in Breast Cancer and Other Tumors
Patra, S., Elahi, N., Armorer, A., Arunachalam, S., Omala, J., Hamid, I., Ashton, A. W., Joyce, D. A., Jiao, X., & Pestell, R. G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.700629 · Cited by 45
Pandit, R., Khadilkar, K. S., Sarathi, V., Kasaliwal, R., Goroshi, M., Khare, S., Nair, S. V. G., Raghavan, V., Dalvi, A. N., Hira, P., et al. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0126 · Cited by 40
Phaeochromocytoma: current concepts
Alderazi, Y., Yeh, M. W., Robinson, B. G., Benn, D. E., Sywak, M. S., Learoyd, D., Delbridge, L., & Sidhu, S. B. (2005) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2005.tb06997.x · Cited by 45
An iron regulatory-like protein expressed in Plasmodium falciparum displays aconitase activity
Hodges, M. G., Yikilmaz, E., Patterson, G. H., Kasvosve, I., Rouault, T. A., Gordeuk, V. R., & Loyevsky, M. (2005) · Molecular and Biochemical Parasitology · doi:10.1016/j.molbiopara.2005.05.004 · Cited by 41
Kim, T., Choi, J., Kim, W. Y., Choi, C. H., Lee, J., Bae, D., Son, D., Kim, J., Park, B. K., Ahn, G., et al. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00652.x · Cited by 39
Von Hippel‐Lindau gene alterations in sporadic benign and malignant pheochromocytomas
Dannenberg, H., de Krijger, R. R., van der Harst, E., Abbou, M., Ijzendoorn, Y., Komminoth, P., & Dinjens, W. N. M. (2003) · International Journal of Cancer · doi:10.1002/ijc.11060 · Cited by 44
van Houtum, W. H., Corssmit, E. P. M., Dekker, P. B. D., Jansen, J. C., van der Mey, A. G. L., Bröcker-Vriends, A. H. J. T., Taschner, P. E. M., Losekoot, M., Frölich, M. A., Stokkel, M. P. M., et al. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01833 · Cited by 44
“Paroxysmal symptoms n ¼ 12 (30) History of hypertension n ¼ 10 ( 25 ) Hypertension n ¼ 26 (65)”
BackgroundBaysal, B. E., Lawrence, E. C., & Ferrell, R. E. (2007) · BMC Biology · doi:10.1186/1741-7007-5-12 · Cited by 39
“Since then, mutations in SDHB, SDHC, and SDHD subunit genes (PGL genes) have been established as an important cause of sporadic and familial paragangliomas [5-10].”
BackgroundPowerhouse down: Complex II dissociation in the respiratory chain
Hwang, M., Rohlena, J., Dong, L., Neužil, J., & Grimm, S. (2014) · Mitochondrion · doi:10.1016/j.mito.2014.06.001 · Cited by 44
Crona, J., Nordling, M., Maharjan, R., Granberg, D. O., Stalberg, P. L. H., Hellman, P., & Björklund, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086756 · Cited by 45
“Arg90* [13] that was present in DNA from blood.”
BackgroundMapping cancer cell metabolism with 13 C flux analysis: Recent progress and future challenges
Young, J., Duckwall, C., & Murphy, T. A. (2013) · Journal of Carcinogenesis · doi:10.4103/1477-3163.115422 · Cited by 52
“[3-5] These results have also paved the way for broader studies implicating elevated glutamine metabolism[6] and glycine and serine biosynthesis[7-9] in cancer progression, as well as recurrent somatic mutations in mitochondrial enzymes such as isocitrate dehydrogenase (IDH),[10,11] fumarase,[12] and succinate dehydro…”
BackgroundManente, A. G., Valenti, D., Pinton, G., Jithesh, P. V., Daga, A., Rossi, L., Gray, S. G., O'Byrne, K. J., Fennell, D. A., Vacca, R. A., et al. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.32 · Cited by 44
New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma
Taïeb, D., & Pacák, K. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.08.001 · Cited by 43
“The prevalence of malignancy is also variable, with a higher rate in SDHB ( 30”
InfluentialZhang, X., Dong, W., Zhang, J., Liu, W., Yin, J., Shi, D., & Ma, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.740487 · Cited by 49
Genetics of familial paragangliomas
Baysal, B. E. (2001) · Otolaryngologic Clinics of North America · doi:10.1016/s0030-6665(05)70352-2 · Cited by 47
Pathogenic mutations of nuclear genes associated with mitochondrial disorders
Zhu, X., Peng, X.-R., Guan, M., & Yan, Q. (2009) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmn021 · Cited by 46
“It comprised four protein subunits encoded by nuclear genes (SDHA, B, C, and D). The homozygous SDHA (flavoprotein subunit) mutations are associated with LS [5], whereas heterozygous mutations in SDHB [ 22 ] (iron–sulfur subunit) and in both SDHC [23] and SDHD [24] (integral membrane-protein subunits) are associated w…”
BackgroundRenal cell carcinoma: translational aspects of metabolism and therapeutic consequences
Yang, O. C. Y., Maxwell, P. H., & Pollard, P. J. (2013) · Kidney International · doi:10.1038/ki.2013.245 · Cited by 41
Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours
Srirangalingam, U., Khoo, B. C. E., Walker, L., MacDonald, F., Skelly, R. H., George, E., Spooner, D. A., Johnston, L., Monson, J. P., Grossman, A. B., et al. (2009) · Endocrine Related Cancer · doi:10.1677/erc-08-0239 · Cited by 41
“The SDHB subjects in this study have been reported previously (Astuti et al. 2001, 2003, Lawrence et al. 2004, Srirangalingam et al. 2008), as have some of the VHL subjects with respect to pancreatic lesions (Mukhopadhyay et al. 2002).”
Self-citationEffects of PPARα inhibition in head and neck paraganglioma cells
Florio, R., Lellis, L. D., di Giacomo, V., Marcantonio, M. C. D., Cristiano, L., Basile, M., Verginelli, F., Verzilli, D., Ammazzalorso, A., Prasad, S. C., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178995 · Cited by 38
Renard, L., Godfraind, C., Boon, L. M., & Vikkula, M. (2003) · Head & Neck · doi:10.1002/hed.10220 · Cited by 38
“Interestingly, pheochromocytomas rather than PGs were frequently observed in the SDHB-linked families.(7) SDHD mutations have also been reported in patients”
BackgroundInfluentialA novel candidate region linked to development of both pheochromocytoma and head/neck paraganglioma
Cascón, A., Ruiz‐Llorente, S., Rodríguez, S., Honrado, E., Martínez‐Ramírez, Á., Letón, R., Montero‐Conde, C., Benitez, J. J., Dopazo, J., Cigudosa, J. C., et al. (2004) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20139 · Cited by 45
“…and PCCs occur sporadically, although about 25% of PCCs and an uncertain percentage of PGLs may be associated with hereditary syndromes (Schimke, 1990; Anderson and Lynch, 1993; Maher et al., 1996; Baysal et al., 2000; Niemann and Muller, 2000; Astuti et al., 2001; Carney and Stratakis, 2002).”
BackgroundMcInerney-Leo, A. M., Marshall, M. S., Gardiner, B., Benn, D. E., McFarlane, J., Robinson, B. G., Brown, M. A., Leo, P. J., Clifton-Bligh, R. J., & Duncan, E. L. (2013) · Clinical Endocrinology · doi:10.1111/cen.12331 · Cited by 39
Misdiagnosis of clear cell renal cell carcinoma
Valera, V., & Merino, M. J. (2011) · Nature Reviews Urology · doi:10.1038/nrurol.2011.64 · Cited by 37
“These tumors usually appear early in life, and seem to develop mostly in people with germline SDHB mutations”
BackgroundTufton, N., Shapiro, L., Srirangalingam, U., Richards, P. S., Sahdev, A., Kumar, A., McAndrew, L., Martin, L., Berney, D. M., Monson, J. P., et al. (2016) · Clinical Endocrinology · doi:10.1111/cen.13246 · Cited by 39
Casey, R. T., McLean, M. A., Madhu, B., Challis, B., ten Hoopen, R., Roberts, T. A., Clark, G. R., Pitfield, D., Simpson, H., Bulusu, V. R., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00191 · Cited by 40
Self-citationOudijk, L., Gaal, J., & de Krijger, R. R. (2018) · Endocrine Pathology · doi:10.1007/s12022-018-9555-2 · Cited by 38
Metabolic Drivers in Hereditary Cancer Syndromes
Sciacovelli, M., Schmidt, C., Maher, E. R., & Frezza, C. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033612 · Cited by 48
Self-citationEpigenetic and metabolic reprogramming of SDH-deficient paragangliomas
Moog, S., Lussey‐Lepoutre, C., & Favier, J. (2020) · Endocrine Related Cancer · doi:10.1530/erc-20-0346 · Cited by 45
High prevalence of occult paragangliomas in asymptomatic carriers of SDHD and SDHB gene mutations
Heesterman, B. L., Bayley, J., Tops, C. M. J., Hes, F. J., van Brussel, B. T. J., Corssmit, E. P. M., Hamming, J. F., van der Mey, A. G. L., & Jansen, J. C. (2012) · European Journal of Human Genetics · doi:10.1038/ejhg.2012.203 · Cited by 37
Aarts, M., Dannenberg, H., deLeeuw, R. J., van Nederveen, F. H., Verhofstad, A. A. J., Lenders, J. W. M., Dinjens, W. N. M., Speel, E. M., Lam, W. L., & de Krijger, R. R. (2005) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20268 · Cited by 44
“13, is the only gene known to be involved in PCC tumorigenesis (Astuti et al., 2001a).”
BackgroundThe first Dutch SDHB founder deletion in paraganglioma – pheochromocytoma patients
Bayley, J., Grimbergen, A., van Bunderen, P. A., van der Wielen, M. J. R., Kunst, H. P. M., Lenders, J. W. M., Jansen, J. C., Dullaart, R. P. F., Devilee, P., Corssmit, E. P. M., et al. (2009) · BMC Medical Genetics · doi:10.1186/1471-2350-10-34 · Cited by 40
“The identification in HN-PGL families of germline mutations of SDHD (succinate dehydrogenase, subunit D) [2] was soon followed by the identification of germline mutations in SDHB [3] and SDHC [4].”
BackgroundParaganglioma Syndrome: SDHB, SDHC, and SDHD Mutations in Head and Neck Paragangliomas
Schiavi, F., Savvoukidis, T., Trabalzini, F., Grego, F., Piazza, M., Amistà, P., Demattè, S., Piano, A. D., Cecchini, M. E., Erlic, Z., et al. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1353.020 · Cited by 41
Adrenal gland and other paraganglia
(2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06969-4.00011-8 · Cited by 41
Mitochondrial superoxide anion (O2·-) inducible "mev-1" animal models for aging research
Ishii, T., Miyazawa, M., Hartman, P. S., & Ishii, N. (2011) · BMB Reports · doi:10.5483/bmbrep.2011.44.5.298 · Cited by 39
“We be- lieve that the mev-1 like cell lines are suitable models for the tumorigenesis in human such as ‘PGL/PHEO syndrome’.”
BackgroundInfluentialToledo, R. A., & Jiménez, C. (2018) · F1000Research · doi:10.12688/f1000research.13995.1 · Cited by 39
Effective, same‐day preoperative embolization and surgical resection of carotid body tumors
Katagiri, K., Shiga, K., Ikeda, A., Saito, D., Oikawa, S., Tsuchida, K., Miyaguchi, J., Tamura, A., Nakasato, T., Ehara, S., et al. (2019) · Head & Neck · doi:10.1002/hed.25805 · Cited by 36
“The disease concept of “hereditary paraganglioma-pheochromocytoma syndrome” has arisen to describe familial paraganglioma patients, and it applies to CBT patients with a family history of the disease and gene alterations.(5-7) It is well known that as malignant tumors cannot always be identified by their morphological…”
BackgroundClinical Experience with Pheochromocytoma in a Single Centre Over 16 Years
Cotesta, D., Petramala, L., Serra, V., Pergolini, M., Crescenzi, E., Zinnamosca, L., Toma, G. D., Ciardi, A., Carbone, I., Massa, R., et al. (2009) · High Blood Pressure & Cardiovascular Prevention · doi:10.2165/11530430-000000000-00000 · Cited by 37
“Nowadays, the mechanism with which a SDHD mutation could determine a tumour of the neuroectodermic tissue is not completely clear, but it has been demonstrated that this mutation results in the loss of function of the II complex,([34]) and the activation of these genes could favour cell growth and tumour formation.”
BackgroundScreening for familial paragangliomas
Myssiorek, D. J., Ferlito, A., Silver, C. E., Rodrigo, J. P., Baysal, B. E., Fagan, J. J., Suarez, C. M., & Rinaldo, A. (2007) · Oral Oncology · doi:10.1016/j.oraloncology.2007.06.010 · Cited by 41
Genetic Testing for Pheochromocytoma-associated Syndromes
Pawlu, C., Bausch, B., Reisch, N., & Neumann, H. P. H. (2005) · Annales d Endocrinologie · doi:10.1016/s0003-4266(05)81749-4 · Cited by 36
Molecular genetic and clinical aspects of mitochondrial disorders in childhood
Moslemi, A., & Darín, N. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.02.002 · Cited by 39
Schaefer, I., Hornick, J. L., & Bovée, J. V. M. G. (2018) · Laboratory Investigation · doi:10.1038/s41374-017-0003-6 · Cited by 38
“Another example of an SDH-deficient GIST with loss of SDHB expression (e) and retained SDHA expression (f) in tumor cells.”
InfluentialRecent Insights into the Molecular Pathogenesis of Pheochromocytoma and Paraganglioma
Nakamura, E., & Kaelin, W. G. (2006) · Endocrine Pathology · doi:10.1385/ep:17:2:97 · Cited by 37
“In the above series, 7 of 10 germline SDHB mutations, all of 3 SDHD mutations, and 1 of 2 germline VHL mutations were associated with LOH in tumor DNA in keeping with the Knudson two-hit model [ 14 ,20,21,27].”
BackgroundResultKeatley, K., Stromei-Cleroux, S., Wiltshire, T., Rajala, N. K. M., Burton, G., Holt, W. V., Littlewood, D. T. J., Briscoe, A. G., Jung, J., Ashkan, K., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133364 · Cited by 36
Phosphoglycerate Dehydrogenase: Potential Therapeutic Target and Putative Metabolic Oncogene
Zogg, C. K. (2014) · Journal of Oncology · doi:10.1155/2014/524101 · Cited by 39
Genetics of Familial Renal Cancers
Maher, E. R. (2010) · Nephron Experimental Nephrology · doi:10.1159/000320892 · Cited by 40
“Thereafter, germline mutations in the B subunit gene (SDHB) were also demonstrated to cause susceptibility to HNPGL and adrenal and extra-adrenal phaeochromocytoma [”
BackgroundSelf-citationCurrent views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma
Vícha, A., Taïeb, D., & Pacák, K. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0398 · Cited by 37
“…al. 1993), the von Hippel–Lindau (VHL; Latif et al. 1993) tumor suppressor, the SDH subunits (SDHA/B/C/D; Baysal et al. 2000, Niemann & Muller 2000, Astuti et al. 2001, Burnichon et al. 2010), SDH complex assembly factor 2 (SDHAF2; Hao et al. 2009), transmembrane protein 127 (TMEM127; Qin et al.…”
Growth Rate of Paragangliomas Related to Germline Mutations of the SDHx Genes
Michałowska, I. M., Ćwikła, J. B., Michalski, W., Wyrwicz, L. S., Prejbisz, A., Szperl, M., Nieć, D., Neumann, H. P. H., Januszewicz, A., & Pęczkowska, M. (2016) · Endocrine Practice · doi:10.4158/ep161377.or · Cited by 38
Santi, R., Rapizzi, E., Canu, L., Ercolino, T., Baroni, G., Fucci, R., COSTA, G., Mannelli, M., & Nesi, G. (2017) · Anticancer Research · doi:10.21873/anticanres.11381 · Cited by 35
Molecular pathogenesis of tumorigenesis caused by succinate dehydrogenase defect
Moosavi, B., Zhu, X., Yang, W., & Yang, G. (2019) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2019.151057 · Cited by 38
Casey, R. T., Neumann, H. P. H., & Maher, E. R. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa201 · Cited by 39
Self-citationIntegrative epigenomic and genomic analysis of malignant pheochromocytoma
Sandgren, J., Andersson, R., Rada-Iglesias, Á., Enroth, S., Åkerström, G., Dumanski, J. P., Komorowski, J., Westin, G., & Wadelius, C. (2010) · Experimental & Molecular Medicine · doi:10.3858/emm.2010.42.7.050 · Cited by 37
“Mutations in the proto-oncogene RET or the tumor suppressor genes VHL, NF1, SDHD, SDHC, and SDHB predisposes to tumor development in these disorders (Xu et al., 1992; Latif et al., 1993; Mulligan et al., 1993; Baysal et al., 2000; Niemann and Muller 2000; Astuti et al., 2001a, 2001b).”
BackgroundHypotension in a Woman with a Metastatic Dopamine-Secreting Carotid Body Tumor
Koch, C. A., Rodbard, J. S., Brouwers, F. M., Eisenhofer, G., & Pacák, K. (2003) · Endocrine Practice · doi:10.4158/ep.9.4.310 · Cited by 35
Fliedner, S. M. J., Kaludercic, N., Jiang, X.-S., Hansíková, H., Hájková, Z., Sládková, J., Limpuangthip, A., Backlund, P. S., WESLEY, R. A., Martiniova, L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040949 · Cited by 37
“Mutations of the SDHx genes can cause pheochromocytomas (PHEOs) and paragangliomas (PGLs) [11,12,13,14].”
BackgroundPanizza, E., Ercolino, T., Mori, L., Rapizzi, E., Castellano, M., Opocher, G., Ferrero, I., Neumann, H. P. H., Mannelli, M., & Goffrini, P. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds487 · Cited by 42
Consensus Statement and Guidelines on the Management of Paragangliomas of the Head and Neck
Gjurić, M., & Gleeson, M. J. (2009) · Skull base · doi:10.1055/s-0028-1103131 · Cited by 37
“from research groups around the world have identified a total of 120 variants.(7,8) Approximately 30% of apparently sporadic H&N PGLs are caused by a germline mutation in one of the genes SDHB, SDHC, and SDHD.”
BackgroundLodish, M. B., Adams, K. T., Huynh, T. T., Prodanov, T., Ling, A. L., Chen, C. C., Shusterman, S., Jiménez, C., Merino, M. J., Hughes, M. S., et al. (2010) · Endocrine Related Cancer · doi:10.1677/erc-10-0004 · Cited by 34
“…from Bioscientifica.com at 05/05/2019 06:13:12AM via free access mitochondrial complex II, have been associated with the development of PGLs (Baysal et al. 2000, Astuti et al. 2001, 2003, Gimenez-Roqueplo et al. 2003, Brouwers et al. 2006, Ghayee et al. 2009).”
Kitazawa, S., Ebara, S., Ando, A., Baba, Y., Satomi, Y., Soga, T., & Hara, T. (2017) · Oncotarget · doi:10.18632/oncotarget.15959 · Cited by 35
Oxidative Phosphorylation System in Gastric Carcinomas and Gastritis
Feichtinger, R. G., Neureiter, D., Skaria, T., Weßler, S., Cover, T. L., Mayr, J. A., Zimmermann, F., Posselt, G., Sperl, W., & Kofler, B. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/1320241 · Cited by 34
Wong, M. Y., Andrews, K. A., Challis, B., Park, S., Acerini, C. L., Maher, E. R., & Casey, R. T. (2018) · Clinical Endocrinology · doi:10.1111/cen.13926 · Cited by 40
Self-citationMitochondrial disorders of the nuclear genome.
Angelini, C. I., Bello, L., Spinazzi, M., & Ferrati, C. (2009) · PubMed Central · Cited by 48
Flynn, A., Dwight, T., Harris, J., Benn, D. E., Zhou, L., Hogg, A., Catchpoole, D. R., James, P. A., Duncan, E. L., Trainer, A. H., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3889 · Cited by 35
Active succinate dehydrogenase (SDH) and lack of SDHD mutations in sporadic paragangliomas.
Braun, S., Riemann, K., Kupka, S., Leistenschneider, P., Sotlar, K., Schmid, H., & Blin, N. (2005) · PubMed · Cited by 38
Routine genetic screening with a multi-gene panel in patients with pheochromocytomas
Sbardella, E., Cranston, T., Isidori, A. M., Shine, B. S. F., Pal, A., Jafar‐Mohammadi, B., Sadler, G., Mihai, R., & Grossman, A. B. (2017) · Endocrine · doi:10.1007/s12020-017-1310-9 · Cited by 35
Guha, A., Musil, Z., Vícha, A., Zelinka, T., Pacák, K., Astl, J., & Chovanec, M. (2019) · Neoplasma · doi:10.4149/neo_2018_181208n933 · Cited by 35
Dorai, T., Sawczuk, I. S., Pastorek, J., Wiernik, P. H., & Dutcher, J. P. (2006) · Cancer Investigation · doi:10.1080/07357900601062321 · Cited by 36
“In the same citric acid cycle reactions, germ line inactivating heterologous mutations in the succinate dehydrogenase complex (SDH B, C, and D) cause hereditary paragangliomas, which are characterized by the development of slow growing, highly vascularized tumors, that can present either as hormonally silent head and…”
BackgroundHensen, E. F., Jansen, J. C., Siemers, M., Oosterwijk, J. C., Vriends, A. H. J. T., Corssmit, E. P. M., Bayley, J., van der Meij, A. G. L., Cornelisse, C. J., & Devilee, P. (2009) · European Journal of Human Genetics · doi:10.1038/ejhg.2009.112 · Cited by 36
Saito, Y., Ishii, K., Aita, Y., Ikeda, T., Kawakami, Y., Shimano, H., Hara, H., & Takekoshi, K. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1738-3 · Cited by 39
Suarez, C. M., Sevilla, M. A., & Llorente, J. L. (2007) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-007-0267-3 · Cited by 37
Oxygen Concentration Controls Epigenetic Effects in Models of Familial Paraganglioma
Her, Y. F., Nelson-Holte, M. H., & Maher, L. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127471 · Cited by 35
Paragangliomas of the Carotid Body: Current Management Protocols and Review of Literature
Naik, S. M., Shenoy, A. M., Nanjundappa, Halkud, R., Chavan, P., Sidappa, K., Amirtham, U., & Gupta, S. (2013) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-013-0249-4 · Cited by 40
Risk‐Oriented Approach to Hereditary Adrenal Pheochromocytoma
Machens, A., Brauckhoff, M., Gimm, O., & Dralle, H. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1353.045 · Cited by 32
Calculating the optimal surveillance for head and neck paraganglioma in SDHB-mutation carriers
Eijkelenkamp, K., Osinga, T. E., de Jong, M. M., Sluiter, W. J., Dullaart, R. P. F., Links, T. P., Kerstens, M. N., & van der Horst‐Schrivers, A. N. A. (2016) · Familial Cancer · doi:10.1007/s10689-016-9923-3 · Cited by 33
“The succinate dehydrogenase subunit B (SDHB) gene is one of the 15 [1] susceptibility genes that have been linked to familial paraganglioma (PGL) and pheochromocytoma (PCC) [2].”
BackgroundMulti-institutional survey of carotid body tumors in Japan
Ikeda, A., Shiga, K., Katagiri, K., Saito, D., Miyaguchi, J., Oikawa, S., Tsuchida, K., Asakage, T., Ozawa, H., Nibu, K., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.7925 · Cited by 32
Tufton, N., Sahdev, A., Drake, W. M., & Akker, S. A. (2018) · Clinical Endocrinology · doi:10.1111/cen.13877 · Cited by 36
“9% (5) – – – Tufton et al24 2016 92 60 18.”
Yuan, T., Zhou, T., Qian, M., Du, J., Liu, Y., Wang, J., Li, Y., Fan, G., Yan, F., Dai, X., et al. (2022) · Hepatology · doi:10.1002/hep.32621 · Cited by 39
Contribution of metabolic abnormalities to acute myeloid leukemia pathogenesis
Egan, G., & Schimmer, A. D. (2022) · Trends in Cell Biology · doi:10.1016/j.tcb.2022.11.004 · Cited by 38
Ricci, L., Stanley, F. U., Eberhart, T., Mainini, F., Sumpton, D. P., & Cardaci, S. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05927-5 · Cited by 41
Germline SDHB Mutations are Common in Patients With Apparently Sporadic Sympathetic Paragangliomas
Klein, R. D., Jin, L. G., Rumilla, K. M., Young, W. F., & Lloyd, R. V. (2008) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e318150d67c · Cited by 34
Pai, R. B., Manipadam, M. T., Singh, P., Ebenazer, A., Samuel, P., & Rajaratnam, S. (2014) · Apmis · doi:10.1111/apm.12269 · Cited by 33
Isocitrate dehydrogenase 1/2 mutational analyses and 2‐hydroxyglutarate measurements in Wilms tumors
Rakheja, D., Mitui, M., Boriack, R. L., & DeBerardinis, R. J. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22697 · Cited by 33
Reduced quality of life in patients with head-and-neck paragangliomas
Havekes, B., van der Klaauw, A. A., Hoftijzer, H. C., Jansen, J. C., van der Mey, A. G. L., Vriends, A. H. J. T., Smit, J. W. A., Romijn, J. A., & Corssmit, E. P. M. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0464 · Cited by 42
Pandit, R., Khadilkar, K. S., Sarathi, V., Kasaliwal, R., Goroshi, M., Khare, S., Nair, S. V. G., Raghavan, V., Dalvi, A. N., Hira, P., et al. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0126e · Cited by 33
From old to new — Repurposing drugs to target mitochondrial energy metabolism in cancer
Aminzadeh-Gohari, S., Weber, D. D., Vidali, S., Catalano, L., Kofler, B., & Feichtinger, R. G. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.025 · Cited by 38
Sandgren, J., de Ståhl, T. D., Andersson, R., Menzel, U., Piotrowski, A., Nord, H., Bäckdahl, M., Kiss, N. B., Brauckhoff, M., Komorowski, J., et al. (2010) · Endocrine Related Cancer · doi:10.1677/erc-09-0310 · Cited by 38
Endocrine Hypertension: Then and Now
Young, W. F. (2010) · Endocrine Practice · doi:10.4158/ep10205.ra · Cited by 33
“Subsequently, mutations in the other succinate dehydrogenase subunit genes (SDHB, SDHC, SDHA, and SDHAF2), which compose portions of mitochondrial complex II, were identified and associated with familial paraganglioma (72-74).”
BackgroundPheochromocytomas and Paragangliomas: Bypassing Cellular Respiration
Cascón, A., Remacha, L., Calsina, B., & Robledo, M. (2019) · Cancers · doi:10.3390/cancers11050683 · Cited by 35
“One year after the finding of the first SDHD germline mutations in patients with PGL, mutations in SDHB, the gene encoding the SDH iron-sulfur subunit, were described as the genetic cause of hereditary PGL type 4 [4].”
Background
Metadata
- Authors
- Astuti, D., Latif, F., Dallol, A., Dahia, P. L. M., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R.
- Affiliations
- University of Birmingham (GB)
- Dana-Farber Cancer Institute (US)
- Royal Victoria Infirmary (GB)
- Queen Elizabeth Hospital (GB)
- Uppsala University (SE)
- University of Cambridge (GB)
- Corresponding author
- Maher, Eamonn R.
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2001-07
- Volume
- 69
- Issue
- 1
- Pages
- 49-54
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC1226047
- OpenAlex
- W2025719835
- Cited by
- 1,087
- References
- 28
- Citations by year
- 2026: 16 · 2025: 18 · 2024: 18 · 2023: 31 · 2022: 29 · 2021: 40 · 2020: 29 · 2019: 51 · 2018: 42 · 2017: 47 · 2016: 54 · 2015: 46 · 2014: 70 · 2013: 61 · 2012: 75
- FWCI
- 37.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 4401 d)
- Locations
- The American Journal of Human Genetics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- British Heart Foundation
- National Cancer Institute (P-30-CA-16058, P30CA016058)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- succinate dehydrogenase, SDHB, SDHC, pheochromocytoma, paraganglioma, germline mutations, mitochondrial dysfunction, sporadic pheochromocytoma, tumor suppressor, RET proto-oncogene, VHL, neurofibromatosis type 1
- MeSH terms
- Proto-Oncogene Mas, Amino Acid Sequence, Base Sequence, DNA Mutational Analysis, Female, Haplotypes, Humans, Male, Molecular Sequence Data, Mutation, Paraganglioma, Pedigree, Pheochromocytoma, Succinate Dehydrogenase, Sequence Alignment, Germ-Line Mutation, Loss of Heterozygosity, Genetic Predisposition to Disease, Mutation, Missense, Protein Subunits
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.